Therapeutic options for 5-lipoxygenase inhibitors.

5-Lipoxygenase (5-LO) catalyzes the conversion of arachidonic acid (AA) into leukotriene (LT) A(4) and 5-hydroperoxyeicosatetraenoic acid. LTA(4) can then be converted into LTB(4) by LTA(4) hydrolase or into LTC(4) by LTC(4) synthase and the LTC(4) synthase isoenzymes MGST2 and MGST3. LTB(4) is a potent chemoattractant for neutrophils, eosinophils and monocytes leading to adherence of phagocytes to vessel walls, neutrophil degranulation and release of superoxide anions. LTC(4) and its metabolite, LTD(4), are potent bronchoconstrictors that increase vascular permeability and stimulate mucus secretion from airways. Recent data also suggest that LT have an immunomodulatory role. Due to these properties, the increased biosynthesis of LT in asthma, and based upon clinical data obtained with CysLT(1) receptor antagonists in asthma patients, there is a consensus that CysLT play a prominent role in asthma. In this review, we summarize the knowledge on possible functions of the 5-LO pathway in various diseases like asthma, cancer and cardiovascular events and review the corresponding potential therapeutic roles of 5-LO inhibitors.

[1]  T. Adrian,et al.  Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  Oliver Werz,et al.  Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. , 2002, Biochemical pharmacology.

[3]  J. Rask-Madsen,et al.  5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease , 2005, Agents and Actions.

[4]  J. Eckman,et al.  Anti-inflammatory activities of LDP-392, a dual PAF receptor antagonist and 5-lipoxygenase inhibitor. , 2001, Pharmacological research.

[5]  G. Wong,et al.  The relation between obesity and asthmatic airway inflammation , 2004, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[6]  Vilmundur Gudnason,et al.  A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction , 2006, Nature Genetics.

[7]  B. Persson,et al.  Membrane-associated proteins in eicosanoid and glutathione metabolism (MAPEG). A widespread protein superfamily. , 2000, American journal of respiratory and critical care medicine.

[8]  O. Werz.  5-lipoxygenase: cellular biology and molecular pharmacology. , 2002, Current drug targets. Inflammation and allergy.

[9]  T. Adrian,et al.  Lipoxygenase inhibitors for the treatment of pancreatic cancer , 2003, Expert review of anticancer therapy.

[10]  M. Fukuda,et al.  A leukotriene receptor antagonist, ONO-1078, modulates drug sensitivity and leukotriene C4 efflux in lung cancer cells expressing multidrug resistance protein. , 1998, Biochemical and biophysical research communications.

[11]  M. Vos,et al.  5‐lipoxygenase inhibitors reduce PC‐3 cell proliferation and initiate nonnecrotic cell death , 1998, The Prostate.

[12]  K. Abe,et al.  Effects of TMK688, a novel anti-allergic drug, on allergic nasal obstruction and exudative responses in sensitized guinea pigs , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[13]  G. Feuerstein.  Leukotrienes and the cardiovascular system. , 1984, Prostaglandins.

[14]  E. Goetzl,et al.  Heterogeneity of Human Polymorphonuclear Leukocyte Receptors for Leukotriene B4 Identification of a Subset of High Affinity Receptors That Transduce the Chemotactic Response , 1980 .

[15]  C. D. Richardson,et al.  5-lipoxygenase-activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase. , 1993, European journal of biochemistry.

[16]  C. Myers,et al.  Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. , 1997, Biochemical and biophysical research communications.

[17]  C. Leslie,et al.  A calcium-dependent mechanism for associating a soluble arachidonoyl-hydrolyzing phospholipase A2 with membrane in the macrophage cell line RAW 264.7. , 1990, The Journal of biological chemistry.

[18]  S. Muro,et al.  5-oxo-6,8,11,14-eicosatetraenoic acid induces the infiltration of granulocytes into human skin. , 2003, The Journal of allergy and clinical immunology.

[19]  M. J. Smith,et al.  Leukotriene B4, a mediator of inflammation present in synovial fluid in rheumatoid arthritis. , 1983, Annals of the rheumatic diseases.

[20]  R. Murphy,et al.  Leukotriene C: a slow-reacting substance from murine mastocytoma cells. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[21]  S. Wang,et al.  Leukotriene A4 hydrolase as a target for cancer prevention and therapy. , 2004, Current cancer drug targets.

[22]  P. V. D. van de Kerkhof,et al.  Topical R-85355, a potent and selective 5-lipoxygenase inhibitor, fails to improve psoriasis. , 1996, Skin pharmacology : the official journal of the Skin Pharmacology Society.

[23]  N. Fusenig,et al.  5-Lipoxygenase expression in Langerhans cells of normal human epidermis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Jilly F. Evans,et al.  The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm , 2004, Nature Medicine.

[25]  R. Snyderman,et al.  Targeted Disruption of the Leukotriene B4Receptor in Mice Reveals Its Role in Inflammation and Platelet-Activating Factor–Induced Anaphylaxis , 2000, The Journal of experimental medicine.

[26]  T. Cohnert,et al.  Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[27]  E. Silverman,et al.  Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. , 1997, The Journal of clinical investigation.

[28]  J. Haeggström.  Leukotriene A4 Hydrolase/Aminopeptidase, the Gatekeeper of Chemotactic Leukotriene B4 Biosynthesis* , 2004, Journal of Biological Chemistry.

[29]  Takao Shimizu,et al.  International Union of Pharmacology XLIV. Nomenclature for the Oxoeicosanoid Receptor , 2004, Pharmacological Reviews.

[30]  J. Rokach,et al.  Biochemistry, biology and chemistry of the 5-lipoxygenase product 5-oxo-ETE. , 2005, Progress in lipid research.

[31]  C. Funk,et al.  The N-terminal “β-Barrel” Domain of 5-Lipoxygenase Is Essential for Nuclear Membrane Translocation* , 2001, The Journal of Biological Chemistry.

[32]  R. Dixon,et al.  Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis , 1990, Nature.

[33]  K. Riesbeck,et al.  A novel localization of the G-protein-coupled CysLT1 receptor in the nucleus of colorectal adenocarcinoma cells. , 2005, Cancer research.

[34]  A. Wildfeuer,et al.  Leukotrienes in the cerebrospinal fluid of multiple sclerosis patients , 1992, Acta neurologica Scandinavica.

[35]  P. Biberfeld,et al.  Studies on the regulation and localization of 5-lipoxygenase in human B-lymphocytes. , 1995, European journal of biochemistry.

[36]  M. Fang,et al.  Overexpression of 5-Lipoxygenase and Cyclooxygenase 2 in Hamster and Human Oral Cancer and Chemopreventive Effects of Zileuton and Celecoxib , 2005, Clinical Cancer Research.

[37]  J. Eckman,et al.  (+/-)-trans-2-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-(N-methyl-N- hydroxyureidyl)methylphenyl]-5-(3,4, 5-trimethoxyphenyl)tetrahydrofuran (CMI-392), a potent dual 5-lipoxygenase inhibitor and platelet-activating factor receptor antagonist. , 1998, Journal of medicinal chemistry.

[38]  E. Sugikawa,et al.  Identification of a Novel Human Eicosanoid Receptor Coupled to Gi/o * , 2002, The Journal of Biological Chemistry.

[39]  U. Thorsteinsdóttir,et al.  Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. , 2005, American journal of human genetics.

[40]  O. Werz,et al.  The C2-like β-Barrel Domain Mediates the Ca2+-dependent Resistance of 5-Lipoxygenase Activity Against Inhibition by Glutathione Peroxidase-1* , 2003, Journal of Biological Chemistry.

[41]  T. Adrian,et al.  Multiple Signal Pathways Are Involved in the Mitogenic Effect of 5(S)-HETE in Human Pancreatic Cancer , 2003, Oncology.

[42]  D. Beer,et al.  Leukotriene A4 hydrolase in rat and human esophageal adenocarcinomas and inhibitory effects of bestatin. , 2003, Journal of the National Cancer Institute.

[43]  Jilly F. Evans,et al.  International Union of Pharmacology XXXVII. Nomenclature for Leukotriene and Lipoxin Receptors , 2003, Pharmacological Reviews.

[44]  John I. Gallin,et al.  Inflammation: Basic Principles and Clinical Correlates , 1992 .

[45]  J. Palmblad,et al.  Dominant Expression of the CysLT2 Receptor Accounts for Calcium Signaling by Cysteinyl Leukotrienes in Human Umbilical Vein Endothelial Cells , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[46]  H. Friess,et al.  THE LEUKOTRIENE RECEPTOR: BLT2R IS OVEREX-PRESSED IN PANCREATIC INTRAEPITHELIAL NEOPLASTIC LESIONS (PANINS): A NEW TARGET FOR THERAPY? , 2004 .

[47]  5-Lipoxygenase, a marker for early pancreatic intraepithelial neoplastic lesions. , 2005 .

[48]  B. Rigas,et al.  Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. , 1995, Biochimica et biophysica acta.

[49]  A. Lusis,et al.  Identification of 5-Lipoxygenase as a Major Gene Contributing to Atherosclerosis Susceptibility in Mice , 2002, Circulation research.

[50]  L. Bonewald,et al.  Mice lacking 5-lipoxygenase have increased cortical bone thickness. , 1997, Advances in experimental medicine and biology.

[51]  M. Yacoub,et al.  Influence of atherosclerosis on the vascular reactivity of isolated human epicardial coronary arteries to leukotriene C4. , 1993, Cardioscience.

[52]  T. Rabe,et al.  Influence of 5-Lipoxygenase on in vitro Growth of Human Mammary Carcinoma Cell Line MCF-7 , 1998, Gynecologic and Obstetric Investigation.

[53]  R. Simon,et al.  A pilot study examining the role of zileuton in atopic dermatitis. , 1999, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[54]  M. Peters-Golden,et al.  Nuclear localization of 5-lipoxygenase as a determinant of leukotriene B4 synthetic capacity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[55]  O. Rådmark.  Arachidonate 5-lipoxygenase. , 2002, Journal of lipid mediators and cell signalling.

[56]  J. Kutok,et al.  Novel lipid mediator regulators of endothelial cell proliferation and migration: aspirin-triggered-15R-lipoxin A(4) and lipoxin A(4). , 2002, The Journal of pharmacology and experimental therapeutics.

[57]  H. Magnussen,et al.  Effects of a 5-lipoxygenase inhibitor, ABT-761, on exercise-induced bronchoconstriction and urinary LTE4 in asthmatic patients. , 1998, The European respiratory journal.

[58]  C. Funk,et al.  Prostaglandins and leukotrienes: advances in eicosanoid biology. , 2001, Science.

[59]  M. H. Lee,et al.  Aspirin-Triggered Lipoxins (15-epi-LX) Are Generated by the Human Lung Adenocarcinoma Cell Line (A549)–Neutrophil Interactions and Are Potent Inhibitors of Cell Proliferation , 1996, Molecular medicine.

[60]  D. Steinhilber.  5-Lipoxygenase: enzyme expression and regulation of activity. , 1994, Pharmaceutica acta Helvetiae.

[61]  J. Ajani,et al.  Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. , 2005, Carcinogenesis.

[62]  J. Pelletier,et al.  Study of the role of leukotriene B()4 in abnormal function of human subchondral osteoarthritis osteoblasts: effects of cyclooxygenase and/or 5-lipoxygenase inhibition. , 2002, Arthritis and rheumatism.

[63]  Luís Vila,et al.  Cyclooxygenase and 5‐lipoxygenase pathways in the vessel wall: Role in atherosclerosis , 2004, Medicinal research reviews.

[64]  D. Bostwick,et al.  Lipoxygenase‐5 is overexpressed in prostate adenocarcinoma , 2001, Cancer.

[65]  Effects of synthetic peptido‐leukotrienes on bone resorption in vitro , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[66]  W. Powell,et al.  Effects of phorbol myristate acetate on the synthesis of 5-oxo-6,8,11,14-eicosatetraenoic acid by human polymorphonuclear leukocytes. , 1994, Biochemistry.

[67]  L. Iversen,et al.  Leukotriene B4 formation during human neutrophil keratinocyte interactions: evidence for transformation of leukotriene A4 by putative keratinocyte leukotriene A4 hydrolase. , 1993, The Journal of investigative dermatology.

[68]  J. Baker,et al.  Dexamethasone increases expression of 5-lipoxygenase and its activating protein in human monocytes and THP-1 cells. , 1997, European journal of biochemistry.

[69]  A. Hatzelmann,et al.  In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis , 2005, Agents and Actions.

[70]  Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. , 2004 .

[71]  W. Feldberg,et al.  Liberation of histamine and formation of lysocithin‐like substances by cobra venom , 1938, The Journal of physiology.

[72]  R. Mansel,et al.  Aberrant expression of 5-lipoxygenase-activating protein (5-LOXAP) has prognostic and survival significance in patients with breast cancer. , 2006, Prostaglandins, leukotrienes, and essential fatty acids.

[73]  M. Yacoub,et al.  Differential leukotriene constrictor responses in human atherosclerotic coronary arteries. , 1998, Circulation.

[74]  L. Bonewald,et al.  Leukotriene B4 stimulates osteoclastic bone resorption both in vitro and in vivo , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[75]  Jilly F. Evans,et al.  Differential Leukotriene Receptor Expression and Calcium Responses in Endothelial Cells and Macrophages Indicate 5-Lipoxygenase–Dependent Circuits of Inflammation and Atherogenesis , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[76]  O. Werz,et al.  1-Oleoyl-2-acetylglycerol Stimulates 5-Lipoxygenase Activity via a Putative (Phospho)lipid Binding Site within the N-terminal C2-like Domain* , 2005, Journal of Biological Chemistry.

[77]  Robert A. Lewis,et al.  Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. , 1990, The New England journal of medicine.

[78]  J. Mulshine,et al.  Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. , 1999, Cancer research.

[79]  H. Claesson,et al.  Asthma and leukotrienes: antileukotrienes as novel anti‐asthmatic drugs , 1999, Journal of internal medicine.

[80]  D. Aronoff,et al.  Phosphorylation by Protein Kinase A Inhibits Nuclear Import of 5-Lipoxygenase* , 2005, Journal of Biological Chemistry.

[81]  Ying Chen,et al.  Inhibition of leukotriene function can modulate particulate-induced changes in bone cell differentiation and activity. , 2001, Journal of biomedical materials research.

[82]  C. Rouzer,et al.  Translocation of 5-lipoxygenase to the membrane in human leukocytes challenged with ionophore A23187. , 1988, The Journal of biological chemistry.

[83]  B. Koller,et al.  Role of the 5-Lipoxygenase–activating Protein (FLAP) in Murine Acute Inflammatory Responses , 1997, The Journal of experimental medicine.

[84]  S. Dahlén,et al.  Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[85]  T. Meitinger,et al.  ALOX5AP Gene and the PDE4D Gene in a Central European Population of Stroke Patients , 2005, Stroke.

[86]  J. Maclouf,et al.  Myocardial protection by the leukotriene synthesis inhibitor BAY X1005: importance of transcellular biosynthesis of cysteinyl-leukotrienes. , 1996, The Journal of pharmacology and experimental therapeutics.

[87]  J. Saffar,et al.  The 5-lipoxygenase inhibitor BWA4C impairs osteoclastic resorption in a synchronized model of bone remodeling. , 1995, Bone.

[88]  T. Adrian,et al.  LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways. , 2005, Biochemical and biophysical research communications.

[89]  O. Werz,et al.  Induction of 5-lipoxygenase activation in polymorphonuclear leukocytes by 1-oleoyl-2-acetylglycerol. , 2003, Biochimica et biophysica acta.

[90]  S. Paruchuri,et al.  The Pro-inflammatory Mediator Leukotriene D4 Induces Phosphatidylinositol 3-Kinase and Rac-dependent Migration of Intestinal Epithelial Cells* , 2005, Journal of Biological Chemistry.

[91]  M. Laviolette,et al.  Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. , 1999, American journal of respiratory and critical care medicine.

[92]  V. Coppola,et al.  5‐Lipoxygenase regulates senescence‐like growth arrest by promoting ROS‐dependent p53 activation , 2005, The EMBO journal.

[93]  Y. Kawahito,et al.  5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway. , 2005, Oncology reports.

[94]  O. Werz,et al.  A test system for leukotriene synthesis inhibitors based on the in-vitro differentiation of the human leukemic cell lines HL-60 and Mono Mac 6 , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[95]  Q. Hamid,et al.  5-oxo-ETE induces pulmonary eosinophilia in an integrin-dependent manner in Brown Norway rats. , 1998, The Journal of clinical investigation.

[96]  N. Flamand,et al.  Cyclic AMP-mediated inhibition of 5-lipoxygenase translocation and leukotriene biosynthesis in human neutrophils. , 2002, Molecular pharmacology.

[97]  S. Charleson,et al.  Leukotrienes C4 and D4 in psoriatic skin lesions. , 1985, Prostaglandins.

[98]  J. Gulcher,et al.  The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke , 2004, Nature Genetics.

[99]  N. Nirmala,et al.  Expression and characterization of a 5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid receptor highly expressed on human eosinophils and neutrophils. , 2003, Molecular pharmacology.

[100]  R. Murphy,et al.  Reversible membrane association of neutrophil 5-lipoxygenase is accompanied by retention of activity and a change in substrate specificity. , 1992, The Journal of biological chemistry.

[101]  T. Adrian,et al.  A novel anti-pancreatic cancer agent, LY293111 , 2005, Anti-cancer drugs.

[102]  W. Lehmann,et al.  Expression of 5-lipoxygenase in differentiating human skin keratinocytes. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[103]  T. Moody,et al.  Five‐lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[104]  E E Schadt,et al.  Integrating genotypic and expression data in a segregating mouse population to identify 5-lipoxygenase as a susceptibility gene for obesity and bone traits , 2005, Nature Genetics.

[105]  J. Miyazaki,et al.  Role of cytosolic phospholipase A2 in allergic response and parturition , 1997, Nature.

[106]  J. Sheller,et al.  5-Lipoxygenase products are necessary for ovalbumin-induced airway responsiveness in mice. , 1997, The American journal of physiology.

[107]  O. Werz,et al.  Arachidonic Acid Promotes Phosphorylation of 5-Lipoxygenase at Ser-271 by MAPK-activated Protein Kinase 2 (MK2)* , 2002, The Journal of Biological Chemistry.

[108]  B. Henderson,et al.  Human chaperonin 60 (Hsp60) stimulates bone resorption: structure/function relationships. , 2003, Bone.

[109]  J. Ghosh,et al.  Expression of 5-oxoETE receptor in prostate cancer cells: critical role in survival. , 2006, Biochemical and biophysical research communications.

[110]  A. Black,et al.  Leukotriene B4‐like material in scale of psoriatic skin lesions , 1984, British journal of pharmacology.

[111]  Jing Wu,et al.  Five‐lipoxygenase‐activating protein inhibitor MK‐886 induces apoptosis in gastric cancer through upregulation of p27kip1 and bax , 2004, Journal of gastroenterology and hepatology.

[112]  M. Goppelt‐Struebe.  Molecular mechanisms involved in the regulation of prostaglandin biosynthesis by glucocorticoids. , 1997, Biochemical pharmacology.

[113]  O. Werz,et al.  Activation of 5-lipoxygenase by cell stress is calcium independent in human polymorphonuclear leukocytes. , 2002, Blood.

[114]  M. Peters-Golden,et al.  Protein Kinase A Inhibits Leukotriene Synthesis by Phosphorylation of 5-Lipoxygenase on Serine 523* , 2004, Journal of Biological Chemistry.

[115]  G. Davı̀,et al.  5‐Lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[116]  O. Werz,et al.  Selenium-dependent peroxidases suppress 5-lipoxygenase activity in B-lymphocytes and immature myeloid cells. The presence of peroxidase-insensitive 5-lipoxygenase activity in differentiated myeloid cells. , 1996, European journal of biochemistry.

[117]  Anatoly L. Mayburd,et al.  Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition. , 2005, Cancer research.

[118]  H E Morton,et al.  MK886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenged leukocytes. , 1990, The Journal of biological chemistry.

[119]  P. Arner,et al.  ALOX5AP expression, but not gene haplotypes, is associated with obesity and insulin resistance , 2006, International Journal of Obesity.

[120]  P. Young,et al.  The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor. , 1992, International journal of immunopharmacology.

[121]  Takao Shimizu,et al.  A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis , 1997, Nature.

[122]  Y. Kanaoka,et al.  Cysteinyl Leukotrienes and Their Receptors: Cellular Distribution and Function in Immune and Inflammatory Responses1 , 2004, The Journal of Immunology.

[123]  C. Owman,et al.  Cloning of cDNA encoding a putative chemoattractant receptor. , 1996, Genomics.

[124]  J. Zakrzewski,et al.  Leukotriene B4 and oral cancer. , 1990, The British journal of oral & maxillofacial surgery.

[125]  O. Werz,et al.  Nonredox 5-lipoxygenase inhibitors require glutathione peroxidase for efficient inhibition of 5-lipoxygenase activity. , 1998, Molecular pharmacology.

[126]  D. Steinhilber.  5-Lipoxygenase: a target for antiinflammatory drugs revisited. , 1999, Current medicinal chemistry.

[127]  O. Werz,et al.  5-lipoxygenase is phosphorylated by p38 kinase-dependent MAPKAP kinases. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[128]  L. Bonewald,et al.  5-Lipoxygenase metabolites of arachidonic acid stimulate isolated osteoclasts to resorb calcified matrices. , 1993, The Journal of biological chemistry.

[129]  C. Myers,et al.  Lipoxygenase Inhibition in Prostate Cancer , 1999, European Urology.

[130]  H. Degreef,et al.  A double-blind vehicle-controlled study of R 68 151 in psoriasis: a topical 5-lipoxygenase inhibitor. , 1990, Journal of the American Academy of Dermatology.

[131]  Nicholas Schork,et al.  Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment , 1999, Nature Genetics.

[132]  R. McMillan.  Leukotrienes in respiratory disease. , 2001, Paediatric respiratory reviews.

[133]  W. Stenson,et al.  Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. , 1984, Gastroenterology.

[134]  J. Haeggström,et al.  Molecular and catalytic properties of three rat leukotriene C(4) synthase homologs. , 2003, Biochemical and biophysical research communications.

[135]  U. V. von Andrian,et al.  Bltr Mediates Leukotriene B4–Induced Chemotaxis and Adhesion and Plays a Dominant Role in Eosinophil Accumulation in a Murine Model of Peritonitis , 2000, The Journal of experimental medicine.

[136]  S. Dahlén,et al.  Allergen challenge of lung tissue from asthmatics elicits bronchial contraction that correlates with the release of leukotrienes C4, D4, and E4. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[137]  O. Werz,et al.  Extracellular signal‐regulated kinases phosphorylate 5lipoxygenase and stimulate 5‐lipoxygenase product formation in leukocytes , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[138]  W. Cunliffe,et al.  A new concept for acne therapy: a pilot study with zileuton, an oral 5-lipoxygenase inhibitor. , 2003, Archives of dermatology.

[139]  A. Castonguay,et al.  Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents. , 1998, Carcinogenesis.

[140]  O. Werz,et al.  Phosphorylation‐ and stimulus‐dependent inhibition of cellular 5‐lipoxygenase activity by nonredox‐type inhibitors , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[141]  J. Ghosh.  Rapid induction of apoptosis in prostate cancer cells by selenium: reversal by metabolites of arachidonate 5-lipoxygenase. , 2004, Biochemical and biophysical research communications.

[142]  H. Friess,et al.  5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. , 2002, The American journal of pathology.

[143]  T. Hori,et al.  Leukotriene B4 Receptor and the Function of Its Helix 8* , 2005, Journal of Biological Chemistry.

[144]  R. D. Dyer,et al.  5-lipoxygenase inhibitory activity of zileuton. , 1991, The Journal of pharmacology and experimental therapeutics.

[145]  J. Bouska,et al.  (R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor. , 1995, Journal of medicinal chemistry.

[146]  T. Moody,et al.  Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. , 1996, The Journal of clinical investigation.

[147]  Diana Murray,et al.  Molecular Basis of the Specific Subcellular Localization of the C2-like Domain of 5-Lipoxygenase* , 2002, The Journal of Biological Chemistry.

[148]  Takao Shimizu,et al.  Stress-induced nuclear export of 5-lipoxygenase. , 2005, Biochemical and biophysical research communications.

[149]  B. Koller,et al.  Collagen-induced Arthritis Is Reduced in 5-Lipoxygenase-activating Protein-deficient Mice , 1997, The Journal of experimental medicine.

[150]  G. Landberg,et al.  Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. , 2003, Gastroenterology.

[151]  D. Kerr,et al.  A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[152]  J. Salmon,et al.  Selective inhibition of arachidonate 5‐lipoxygenase by novel acetohydroxamic acids: biochemical assessment in vitro and ex vivo , 1988, British journal of pharmacology.

[153]  C. Myers,et al.  Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[154]  T. Lewis,et al.  5-lipoxygenase inhibitors with histamine H(1) receptor antagonist activity. , 2004, Bioorganic & medicinal chemistry letters.

[155]  Jun Jiang,et al.  LTB4 Can Directly Stimulate Human Osteoclast Formation from PBMC Independent of RANKL , 2005, Artificial cells, blood substitutes, and immobilization biotechnology.

[156]  J. Mancini,et al.  5-Lipoxygenase-activating protein homodimer in human neutrophils: evidence for a role in leukotriene biosynthesis. , 2006, The Biochemical journal.

[157]  D. Riendeau,et al.  Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor. , 1992, Canadian journal of physiology and pharmacology.

[158]  Letts Lg.  Leukotrienes: role in cardiovascular physiology. , 1987 .

[159]  L. Bonewald,et al.  Avian Osteoclast Cells are Stimulated to Resorb Calcified Matrices by and Possess Receptors for Leukotriene B4 , 1999, Calcified Tissue International.

[160]  P. Vickers,et al.  5-Lipoxygenase-activating protein (FLAP). , 1995, Journal of lipid mediators and cell signalling.

[161]  H. Vinters,et al.  Differential expression of arachidonate 5-lipoxygenase transcripts in human brain tumors: evidence for the expression of a multitranscript family. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[162]  H. Showell,et al.  Leukotriene B4 Receptor Antagonism Reduces Monocytic Foam Cells in Mice , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[163]  S. Charleson,et al.  5‐lipoxygenase‐activating protein is an arachidonate binding protein , 1993, FEBS letters.

[164]  D. Steinhilber,et al.  Expression of 5-lipoxygenase by human colorectal carcinoma Caco-2 cells during butyrate-induced cell differentiation. , 2000, Biochemical and biophysical research communications.

[165]  R. McMillan,et al.  Designing therapeutically effective 5-lipoxygenase inhibitors. , 1992, Trends in pharmacological sciences.

[166]  G. Freeman,et al.  Expression cloning of a cDNA for human leukotriene C4 synthase, an integral membrane protein conjugating reduced glutathione to leukotriene A4. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[167]  O. Werz,et al.  Pharmacological intervention with 5-lipoxygenase: new insights and novel compounds , 2005 .

[168]  X. Ding,et al.  Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells. , 1999, Biochemical and biophysical research communications.

[169]  K. Kashfi,et al.  The effect of leukotrienes B and selected HETEs on the proliferation of colon cancer cells. , 1996, Biochimica et biophysica acta.

[170]  K. Entian,et al.  The 5-Lipoxygenase Promoter Is Regulated by DNA Methylation* , 2002, The Journal of Biological Chemistry.

[171]  S. Dahlén,et al.  Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. , 1987, Science.

[172]  T. Abram,et al.  BAY u9773, a novel antagonist of cysteinyl-leukotrienes with activity against two receptor subtypes. , 1994, European journal of pharmacology.

[173]  A. Wendel,et al.  Selenoenzymes regulate the activity of leukocyte 5-lipoxygenase via the peroxide tone. , 1993, The Journal of biological chemistry.

[174]  C. Funk.  The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase-deficient mice. , 1996, Biochimica et biophysica acta.

[175]  S. McColl,et al.  Studies on the activation of human neutrophil 5-lipoxygenase induced by natural agonists and Ca2+ ionophore A23187. , 1991, The Biochemical journal.

[176]  E. Lobos,et al.  Chemotactic activity in inflammatory bowel disease , 1987, Digestive Diseases and Sciences.

[177]  K. Austen,et al.  Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[178]  R. McMillan,et al.  Methoxytetrahydropyrans. A new series of selective and orally potent 5-lipoxygenase inhibitors. , 1992, Journal of medicinal chemistry.

[179]  J. Kemp.  Recent Advances in the Management of Asthma Using Leukotriene Modifiers , 2003, American journal of respiratory medicine : drugs, devices, and other interventions.

[180]  J. Ghosh.  Inhibition of arachidonate 5-lipoxygenase triggers prostate cancer cell death through rapid activation of c-Jun N-terminal kinase. , 2003, Biochemical and biophysical research communications.

[181]  R. Dziak,et al.  Effects of leukotrienes on osteoblastic cell proliferation , 1991, Calcified Tissue International.

[182]  D. Steinhilber,et al.  Serum factors regulate 5-lipoxygenase activity in maturating HL60 cells. , 1993, Biochimica et biophysica acta.

[183]  S. Ludwin,et al.  Microarray analysis of gene expression in multiple sclerosis and EAE identifies 5-lipoxygenase as a component of inflammatory lesions , 2001, Journal of Neuroimmunology.

[184]  T. Adrian,et al.  Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. , 2002, Molecular cancer therapeutics.

[185]  Jilly F. Evans,et al.  Identification and isolation of a membrane protein necessary for leukotriene production , 1990, Nature.

[186]  D. Riendeau,et al.  Cellular Oxygenation of 12-Hydroxyeicosatetraenoic Acid and 15-Hydroxyeicosatetraenoic Acid by 5-Lipoxygenase Is Stimulated by 5-Lipoxygenase-activating Protein* , 1998, The Journal of Biological Chemistry.

[187]  T. Hullinger,et al.  The effect of a novel, dual function histamine H1 receptor antagonist/5-lipoxygenase enzyme inhibitor on in vivo dermal inflammation and extravasation. , 2005, European journal of pharmacology.

[188]  L. Bonewald,et al.  5-Lipoxygenase metabolites inhibit bone formation in vitro. , 1998, Endocrinology.

[189]  R. de Caterina,et al.  Leukotriene B4 production in human atherosclerotic plaques. , 1988, Biomedica biochimica acta.

[190]  R. Haggitt,et al.  Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591. , 1997, Gastroenterology.

[191]  J. Suttles,et al.  Role of Leukotriene B4 Receptors in the Development of Atherosclerosis: Potential Mechanisms , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[192]  S. Soddu,et al.  5‐Lipoxygenase antagonizes genotoxic stress‐induced apoptosis by altering p53 nuclear trafficking , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[193]  B. Pace,et al.  Zileuton induces hemoglobin F synthesis in erythroid progenitors: role of the L-arginine-nitric oxide signaling pathway. , 2004, Blood.

[194]  D. Gudbjartsson,et al.  Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. , 2005, Journal of the American Medical Association (JAMA).

[195]  J. Falgueyret,et al.  Naphthalenic lignan lactones as selective, nonredox 5-lipoxygenase inhibitors. Synthesis and biological activity of (methoxyalkyl)thiazole and methoxytetrahydropyran hybrids. , 1994, Journal of medicinal chemistry.

[196]  C. Woo,et al.  Role of the BLT2, a leukotriene B4 receptor, in Ras transformation , 2004, Oncogene.

[197]  Zhihua Liu,et al.  The deregulation of arachidonic acid metabolism‐related genes in human esophageal squamous cell carcinoma , 2003, International journal of cancer.

[198]  S. Laufer,et al.  The pharmacological profile of ML3000: A new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase , 2001, InflammoPharmacology.

[199]  C. Shapleigh,et al.  Lipoxygenation of arachidonic acid as a source of polymorphonuclear leukocyte chemotactic factors in synovial fluid and tissue in rheumatoid arthritis and spondyloarthritis. , 1980, The Journal of clinical investigation.

[200]  J. Kremer,et al.  Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis. , 1992, The Journal of rheumatology.

[201]  T. Lewis,et al.  5-Lipoxygenase inhibition by N-hydroxycarbamates in dual-function compounds. , 2005, Bioorganic & medicinal chemistry letters.

[202]  L. Dubé,et al.  A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group For Ulcerative Colitis. , 1997, Gastroenterology.